GILD has performed well in the past six months, with new drug approvals, positive data readouts and strong quarterly results.

Gilead Sciences and the U.S. government have settled a billion-dollar patent dispute over Gilead's HIV prevention drugs ...

Shares of Gilead Sciences Inc. GILD rallied 1.52% to $92.38 Wednesday, on what proved to be an all-around great trading ...

Zacks Research boosted their Q2 2025 earnings per share estimates for Gilead Sciences in a report issued on Thursday, January ...

Gilead Sciences Inc (GILD) stock saw a modest uptick, ending the day at $91.84 which represents a slight increase of $0.19 or 0.21% from the prior close of $91.65. The stock opened at $92.01 and ...

We recently published a list of 15 Best NASDAQ Dividend Stocks To Buy. In this article, we are going to take a look at where ...

Global leaders must urgently prioritise and work to provide access to new long-acting HIV prevention -- and potentially ...

Park Avenue Securities LLC grew its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 31.4% during the ...

Jefferies analyst Michael Yee maintained a Buy rating on Gilead Sciences (GILD – Research Report) yesterday and set a price target of ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Terms of the deal were not disclosed in the case, which involved the government’s patents on Gilead’s HIV drugs Truvada and ...

Gilead Sciences’ Livdelzi (seladelpar) has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) to treat adults with the rare liver disease primary biliary cholangitis (PBC) ...